Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inactivation of the PI3K/AKT pathway in human pancreatic cancer cells

Cancer Letters

Volumn 357, Issue 1, 2015, Pages 219-230

  Li, Xu ^a   Zhu, Feng ^a   Jiang, Jianxin ^b   Sun, Chengyi ^b   Wang, Xin ^a   Shen, Ming ^a   Tian, Rui ^a   Shi, Chengjian ^a   Xu, Meng ^a   Peng, Feng ^a   Guo, Xingjun ^a   Wang, Min ^a   Qin, Renyi ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b GUIZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Oxaliplatin; Pancreatic cancer; PI3K AKT pathway; ROS; Withaferin A

Indexed keywords

ACETYLCYSTEINE; BIM PROTEIN; CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; MALONALDEHYDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN KINASE B; PROTEIN MCL 1; REACTIVE OXYGEN METABOLITE; WITHAFERIN A; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX; WITHANOLIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME DEGRADATION; ENZYME INACTIVATION; ENZYME REGULATION; ENZYME RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; NUDE MOUSE; PANCREATIC NEOPLASMS; PROGNOSIS; RANDOMIZATION; SIGNAL TRANSDUCTION;

WITHANIA SOMNIFERA;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; DRUG SYNERGISM; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; RANDOM ALLOCATION; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; WITHANOLIDES;

EID: 84920496306     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.11.026     Document Type: Article

References (50)

1. Michl P., Gress T.M. Current concepts and novel targets in advanced pancreatic cancer. Gut 2013, 62:317-326.
2. Oettle H., Post S., Neuhaus P., Gellert K., Langrehr J., Ridwelski K., et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007, 297:267-277.
3. Kindler H.L., Niedzwiecki D., Hollis D., Sutherland S., Schrag D., Hurwitz H., et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol 2010, 28:3617-3622.
4. Androulakis N., Syrigos K., Polyzos A., Aravantinos G., Stathopoulos G.P., Ziras N., et al. Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study. Cancer Invest 2005, 23:9-12.
5. Saif M.W., Kim R. Role of platinum agents in the management of advanced pancreatic cancer. Expert Opin. Pharmacother 2007, 8:2719-2727.
6. Novarino A., Satolli M.A., Chiappino I., Giacobino A., Bellone G., Rahimi F., et al. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer. Am. J. Clin. Oncol 2009, 32:44-48.
7. Lee K.H., Kim M.K., Kim Y.H., Ryoo B.Y., Lim H.Y., Song H.S., et al. Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study. Cancer Chemother. Pharmacol 2009, 64:317-325.
8. Pelzer U., Schwaner I., Stieler J., Adler M., Seraphin J., Dörken B., et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur. J. Cancer 2011, 47:1676-1681.
9. Melisi D., Ossovskaya V., Zhu C., Rosa R., Ling J., Dougherty P.M., et al. Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity. Clin. Cancer Res 2009, 15:6367-6377.
10. Vanden Berghe W., Sabbe L., Kaileh M., Haegeman G., Heyninck K. Molecular insight in the multifunctional activities of Withaferin A. Biochem. Pharmacol 2012, 84:1282-1291.
11. Oh J.H., Kwon T.K. Withaferin A inhibits tumor necrosis factor-alpha-induced expression of cell adhesion molecules by inactivation of Akt and NF-kappaB in human pulmonary epithelial cells. Int. Immunopharmacol 2009, 9:614-619.
12. Srinivasan S., Ranga R.S., Burikhanov R., Han S.S., Chendil D. Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells. Cancer Res 2007, 67:246-253.
13. Stan S.D., Hahm E.R., Warin R., Singh S.V. Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo. Cancer Res 2008, 68:7661-7669.
14. Koduru S., Kumar R., Srinivasan S., Evers M.B., Damodaran C. Notch-1 inhibition by Withaferin-A: a therapeutic target against colon carcinogenesis. Mol. Cancer Ther 2010, 9:202-210.
15. Lee T.J., Um H.J., Min do S., Park J.W., Choi K.S., Kwon T.K. Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Free Radic. Biol. Med 2009, 46:1639-1649.
16. Fong M.Y., Jin S., Rane M., Singh R.K., Gupta R., Kakar S.S. Withaferin A synergizes the therapeutic effect of doxorubicin through ROS-mediated autophagy in ovarian cancer. PLoS ONE 2012, 7:e42265.
17. Cohen S.M., Mukerji R., Timmermann B.N., Samadi A.K., Cohen M.S. A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers. Am. J. Surg 2012, 204:895-900.
18. Crescenzi E., Chiaviello A., Canti G., Reddi E., Veneziani B.M., Palumbo G. Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non-small cell lung cancer cells (H1299). Mol. Cancer Ther 2006, 5:776-785.
19. Kroemer G., Galluzzi L., Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev 2007, 87:99-163.
20. Tait S.W., Green D.R. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat. Rev. Mol. Cell Biol 2010, 11:621-632.
21. Circu M.L., Aw T.Y. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic. Biol. Med 2010, 48:749-762.
22. Nogueira V., Hay N. Molecular pathways: reactive oxygen species homeostasis in cancer cells and implications for cancer therapy. Clin. Cancer Res 2013, 19:4309-4314.
23. Kopetz S., Lesslie D.P., Dallas N.A., Park S.I., Johnson M., Parikh N.U., et al. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 2009, 69:3842-3849.
24. Ding Z.B., Hui B., Shi Y.H., Zhou J., Peng Y.F., Gu C.Y., et al. Autophagy activation in hepatocellular carcinoma contributes to the tolerance of oxaliplatin via reactive oxygen species modulation. Clin. Cancer Res 2011, 17:6229-6238.
25. Hahm E.R., Moura M.B., Kelley E.E., Van Houten B., Shiva S., Singh S.V. Withaferin A-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species. PLoS ONE 2011, 6:e23354.
26. Mayola E., Gallerne C., Esposti D.D., Martel C., Pervaiz S., Larue L., et al. Withaferin A induces apoptosis in human melanoma cells through generation of reactive oxygen species and down-regulation of Bcl-2. Apoptosis 2011, 16:1014-1027.
27. Grogan P.T., Sleder K.D., Samadi A.K., Zhang H., Timmermann B.N., Cohen M.S. Cytotoxicity of withaferin A in glioblastomas involves induction of an oxidative stress-mediated heat shock response while altering Akt/mTOR and MAPK signaling pathways. Invest. New Drugs 2013, 31:545-557.
28. Altomare D.A., Tanno S., De Rienzo A., Klein-Szanto A.J., Tanno S., Skele K.L., et al. Frequent activation of AKT2 kinase in human pancreatic carcinomas. J. Cell. Biochem 2002, 87:470-476.
29. Yamamoto S., Tomita Y., Hoshida Y., Morooka T., Nagano H., Dono K., et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin. Cancer Res 2004, 10:2846-2850.
30. Oh J.H., Lee T.J., Kim S.H., Choi Y.H., Lee S.H., Lee J.M., et al. Induction of apoptosis by withaferin A in human leukemia U937 cells through down-regulation of Akt phosphorylation. Apoptosis 2008, 13:1494-1504.
31. Samadi A.K., Cohen S.M., Mukerji R., Chaguturu V., Zhang X., Timmermann B.N., et al. Natural withanolide withaferin A induces apoptosis in uveal melanoma cells by suppression of Akt and c-MET activation. Tumour Biol 2012, 33:1179-1189.
32. Hyun M.S., Hur J.M., Mun Y.J., Kim D., Woo W.H. BBR induces apoptosis in HepG2 cell through an Akt-ASK1-ROS-p38MAPKs-linked cascade. J. Cell. Biochem 2010, 109:329-338.
33. Liu C., Gong K., Mao X., Li W. Tetrandrine induces apoptosis by activating reactive oxygen species and repressing Akt activity in human hepatocellular carcinoma. Int. J. Cancer 2011, 129:1519-1531.
34. Fulda S., Debatin K.M. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 2004, 64:337-346.
35. Banerjee S., Wang Z., Kong D., Sarkar F.H. 3,3'-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res 2009, 69:5592-5600.
36. Ghobrial I.M., Witzig T.E., Adjei A.A. Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin 2005, 55:178-194.
37. Ghavami S., Hashemi M., Ande S.R., Yeganeh B., Xiao W., Eshraghi M., et al. Apoptosis and cancer: mutations within caspase genes. J. Med. Genet 2009, 46:497-510.
38. Shimizu S., Narita M., Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 1999, 399:483-487.
39. Harris M.H., Thompson C.B. The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ 2000, 7:1182-1191.
40. Kantari C., Walczak H. Caspase-8 and bid: caught in the act between death receptors and mitochondria. Biochim. Biophys. Acta 2011, 1813:558-563.
41. Teoh M.L., Sun W., Smith B.J., Oberley L.W., Cullen J.J. Modulation of reactive oxygen species in pancreatic cancer. Clin. Cancer Res 2007, 13:7441-7450.
42. Trachootham D., Lu W., Ogasawara M.A., Nilsa R.D., Huang P. Redox regulation of cell survival. Antioxid. Redox Signal 2008, 10:1343-1374.
43. Schumacker P.T. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 2006, 10:175-176.
44. Takeda S., Noguchi M., Matsuo K., Yamaguchi Y., Kudo T., Nishimura H., et al. (-)-Xanthatin up-regulation of the GADD45γ tumor suppressor gene in MDA-MB-231 breast cancer cells: role of topoisomerase IIα inhibition and reactive oxygen species. Toxicology 2013, 305:1-9.
45. Kim D.S., Jeon B.K., Lee Y.E., Woo W.H., Mun Y.J. Diosgenin induces apoptosis in HepG2 cells through generation of reactive oxygen species and mitochondrial pathway. Evid. Based Complement. Alternat. Med 2012, 98:1675.
46. Hafsi S., Pezzino F.M., Candido S., Ligresti G., Spandidos D.A., Soua Z., et al. Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). Int. J. Oncol 2012, 40:639-644.
47. Leake K., Singhal J., Nagaprashantha L.D., Awasthi S., Singhal S.S. RLIP76 regulates PI3K/Akt signaling and chemo-radiotherapy resistance in pancreatic cancer. PLoS ONE 2012, 7:e34582.
48. Yang E.S., Choi M.J., Kim J.H., Choi K.S., Kwon T.K. Withaferin A enhances radiation-induced apoptosis in Caki cells through induction of reactive oxygen species, Bcl-2 downregulation and Akt inhibition. Chem. Biol. Interact 2011, 190:9-15.
49. Mandal C., Dutta A., Mallick A., Chandra S., Misra L., Sangwan R.S., et al. Withaferin A induces apoptosis by activating p38 mitogen-activated protein kinase signaling cascade in leukemic cells of lymphoid and myeloid origin through mitochondrial death cascade. Apoptosis 2008, 13:1450-1464.
50. Hahm E.R., Lee J., Singh S.V. Role of mitogen-activated protein kinases and Mcl-1 in apoptosis induction by withaferin A in human breast cancer cells. Mol. Carcinog 2014, 53:907-916.